This trial is testing a new cancer drug to see if it is safe and works well with other cancer treatments. They will also look at how the body processes the drug.
4 Primary · 6 Secondary · Reporting Duration: Assessed up to 24 months from time of first dose
Experimental Treatment
200 Total Participants · 8 Treatment Groups
Primary Treatment: ERAS-007 · No Placebo Group · Phase 1 & 2
Age 18 - 99 · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: